CLOUDBREAK THERAPEUTICS LLC
Topical ophthalmic emulsion formulation of nintedanib (CBT-001), a small molecule multikinase inhibitor for treating pterygium
- Sector
- Medtech
- Headquarters
- Irvine, CA
- Total capital
- $5M
- Federal grants
- $5M
- 7 awards · 2018–2021
- Rank in peer group#20 of 30
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 11
- 17 pending · first 2018
- Rank in peer group#1 of 30
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · A Phase 3 Multicenter, Randomized, Vehicle-Controlled Clinical Study to Evaluate the Safety and Efficacy of an Ophthalmic Emulsion of Nintedanib in Pterygium Patients$678K
- Federal grantHealth and Human S · Phase II · A Phase 3 Multicenter, Randomized, Vehicle-Controlled Clinical Study to Evaluate the Safety and Efficacy of an Ophthalmic Emulsion of Nintedanib in Pterygium Patients$1.4M
- Federal grantHealth and Human S · Phase II · A Phase 3 Multicenter, Randomized, Vehicle-Controlled Clinical Study to Evaluate the Safety and Efficacy of an Ophthalmic Emulsion of Nintedanib in Pterygium Patients$700K
- Federal grantHealth and Human S · Phase II · A Phase 2a Multicenter, Randomized, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety, Efficacy and Pharmacokinetics of CBT-001 Ophthalmic Solution in Pterygium Patients$809K
- Federal grantHealth and Human S · Phase II · A Phase 2a Multicenter, Randomized, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety, Efficacy and Pharmacokinetics of CBT-001 Ophthalmic Solution in Pterygium Patients$739K
- Federal grantHealth and Human S · Phase II · A Phase 2a Multicenter, Randomized, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety, Efficacy and Pharmacokinetics of CBT-001 Ophthalmic Solution in Pterygium Patients$385K
- Federal grantHealth and Human S · Phase II · A Phase 2a Multicenter, Randomized, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety, Efficacy and Pharmacokinetics of CBT-001 Ophthalmic Solution in Pterygium Patients$327K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 30 peers
Line = medianMedtech · Molecule
- Federal grantsBelow median
- Granted patents#1 · top 3%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 11 granted of 28- PendingCompositions And Methods For Treating Pterygium RecurrenceUSPTOApplication 18968493
- GrantedCompositions And Methods For Treating Pterygium RecurrenceUSPTOUS 12,186,424
- PendingEmulsion Formulations Of Multikinase InhibitorsUSPTOApplication 18307449
Show all 28 patent records
- Compositions And Methods For Treating Pterygium RecurrenceAug 21, 2025 · Application 18968493Pending
- Compositions And Methods For Treating Pterygium RecurrenceJan 7, 2025 · US 12,186,424Granted
- Emulsion Formulations Of Multikinase InhibitorsNov 30, 2023 · Application 18307449Pending
- Emulsion Formulations Of Multikinase InhibitorsJun 6, 2023 · US 11,666,533Granted
- Methods For Alleviating Pterygium-associated Worry About Eye AppearanceOct 20, 2022 · Application 17640889Pending
- Emulsion Formulations Of Multikinase InhibitorsOct 14, 2021 · Application 17272105Pending
- Compositions And Methods For Treating Eye DiseasesMay 18, 2021 · US 11,007,214Granted
- Compositions And Methods For Treating Pterygium RecurrenceApr 20, 2021 · US 10,980,741Granted
- Compositions And Methods For Treating Meibomian Gland DysfunctionAug 18, 2020 · US 10,744,153Granted
- Compositions And Methods Of Using Nintedanib For Improving Glaucoma Surgery SuccessJun 23, 2020 · US 10,688,092Granted
- Compositions And Methods Of Using Nintedanib For Improving Glaucoma Surgery SuccessJul 2, 2019 · US 10,335,408Granted
- Compositions And Methods For Treating HyperemiaDec 11, 2018 · US 10,149,819Granted
- Compositions And Methods For Treating PterygiumDec 11, 2018 · US 10,149,820Granted
- Compositions And Methods For Treating PterygiumJun 5, 2018 · US 9,987,223Granted
- Compositions And Methods For Treating PterygiumMay 29, 2018 · US 9,980,901Granted
- Esters Of 8-METHYL-8-AZABICYCLO[3.2.1] OCTAN-3-YL 3-HYDROXY-2-PHENYLPROPANOATEApplication 63301657Pending
- Emulsion Formulations Of Multikinase InhibitorsApplication 62723998Pending
- Compositions And Methods Of Using Nintedanib For Treating Ocular Diseases With Abnormal NeovascularizationApplication PCTUS2017034795Pending
- Compositions And Methods Of Using Nintedanib For Improving Glaucoma Surgery SuccessApplication PCTUS2017034792Pending
- Compositions And Methods For Treating PterygiumApplication PCTUS2016035726Pending
- Methods for Improving Corneal Transplant Success and Treatment of Other Front of the Eye Diseases with Neovascularization ComponentApplication 62344870Pending
- Methods for Improving the Success Rate of Glaucoma Surgery and Neovascular Glaucoma TreatmentApplication 62344878Pending
- Topical Ophthalmological Compositions And Methods For Treating Abnormal AngiogenesisApplication 63032920Pending
- Medical Treatment for Pterygium PatientsApplication 62172063Pending
- Cyclodextrin Ophthalmic Compositions And Methods Of Using The SameApplication 62903898Pending
- Methods For Alleviating Pterygium-associated Worry About Eye AppearanceApplication 62898401Pending
- Emulsion Formulations Of Multikinase InhibitorsApplication PCTUS2019048635Pending
- Methods For Alleviating Pterygium-associated Worry About Eye AppearanceApplication PCTUS2020050150Pending
Related companies, and why
- NOCTURNAL PRODUCT DEVELOPMENT, LLCSimilar federal contract value in Medtech · null in contracts
- CYTHORSimilar federal contract value in Medtech · null in contracts
- ADVENT THERAPEUTICS INCSimilar federal contract value in Medtech · null in contracts
- NEUROSCOPE INC.Similar federal contract value in Medtech · null in contracts
- AUGDIMER, LLCSimilar federal contract value in Medtech · null in contracts
- LifeAire Systems, LLCSimilar federal contract value in Medtech · null in contracts
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .